23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
23:17 , May 24, 2018 |  BC Innovations  |  Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

Patritumab: Phase III discontinued

Daiichi discontinued the double-blind, placebo-controlled, international Phase III HER3-Lung trial of IV patritumab after an IDMC concluded the study’s first part assessing PFS did not meet the predefined efficacy criteria. The IDMC did not identify...
07:00 , Mar 28, 2016 |  BioCentury  |  Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Seribantumab: Phase II amended

Merrimack amended an open-label, international Phase II trial of IV MM-121 to change the primary endpoint to OS from PFS to support potential registration. The trial is comparing MM-121 plus investigator’s choice of docetaxel or...
07:00 , Sep 10, 2015 |  BC Innovations  |  Emerging Company Profile

Epitope as prologue

Most antibody platforms target specific antigens, but offer little control over the exact binding location on the target or how the antibody affects activity. Hummingbird Bioscience Pte. Ltd. has developed a system for pinpointing the...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

MM-121: Phase II started

Merrimack began an open-label, international Phase II trial to compare MM-121 plus docetaxel or pemetrexed vs. docetaxel or pemetrexed alone in about 120 patients who have progressed following <=2 prior systemic therapies. Merrimack Pharmaceuticals Inc...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

MM-121: Additional Phase II data

Last year, Merrimack disclosed on a conference call to discuss its 2Q13 earnings that a pre-specified interim analysis of the trial by a DSMB showed that MM-121 plus paclitaxel would not meet the primary endpoint....